SAN DIEGO--(BUSINESS WIRE)--MultiCell Technologies, Inc. (OTCBB: MCET), developing first-in-class drugs based on advanced immune system modulation and other proprietary technologies, will hold an investor conference call on Wed, October 25, at 12 noon Eastern, to update investors on its key drug development programs and continued expansion of its intellectual property portfolio.
